R1 Launches 'R37': An AI Lab to Transform Healthcare Financial Performance in Exclusive Partnership with Palantir
R1 and Palantir Technologies (NASDAQ:PLTR) have partnered to launch R37, an advanced AI lab focused on transforming healthcare financial performance. The collaboration combines R1's extensive revenue cycle management expertise with Palantir's AI capabilities to develop intelligent automation solutions for healthcare reimbursement challenges.
The initiative addresses a critical need, as administrative costs represent over 40% of U.S. hospital expenses, with more than $160 billion spent annually on revenue cycle management. R1's substantial reach, serving 94 of the top 100 U.S. health systems, provides access to extensive data including:
- 180 million+ annual payer transactions
- 550 million annual patient encounters
- 20,000 proprietary payment algorithms
- 1.2 billion annual workflow actions
The lab, already operational, is developing AI-powered applications for tasks like coding, billing, and denials management. R1 plans to deploy comprehensive 'agentic RCM worker' solutions to enterprise customers in the second half of 2025.
R1 e Palantir Technologies (NASDAQ:PLTR) hanno stretto una partnership per lanciare R37, un laboratorio avanzato di intelligenza artificiale focalizzato sulla trasformazione delle performance finanziarie nel settore sanitario. La collaborazione unisce l'ampia esperienza di R1 nella gestione del ciclo di entrate con le capacità di intelligenza artificiale di Palantir per sviluppare soluzioni di automazione intelligente per affrontare le sfide del rimborso sanitario.
L'iniziativa risponde a un bisogno critico, poiché i costi amministrativi rappresentano oltre il 40% delle spese ospedaliere negli Stati Uniti, con oltre 160 miliardi di dollari spesi annualmente nella gestione del ciclo di entrate. L'ampia portata di R1, che serve 94 dei 100 principali sistemi sanitari statunitensi, fornisce accesso a un vasto insieme di dati, tra cui:
- oltre 180 milioni di transazioni annuali dei pagatori
- 550 milioni di incontri annuali con i pazienti
- 20.000 algoritmi di pagamento proprietari
- 1,2 miliardi di azioni di flusso di lavoro annuali
Il laboratorio, già operativo, sta sviluppando applicazioni potenziate dall'intelligenza artificiale per compiti come codifica, fatturazione e gestione dei rifiuti. R1 prevede di implementare soluzioni complete per 'lavoratori RCM agentici' ai clienti aziendali nella seconda metà del 2025.
R1 y Palantir Technologies (NASDAQ:PLTR) se han asociado para lanzar R37, un laboratorio avanzado de inteligencia artificial enfocado en transformar el rendimiento financiero en el sector de la salud. La colaboración combina la amplia experiencia de R1 en la gestión del ciclo de ingresos con las capacidades de inteligencia artificial de Palantir para desarrollar soluciones de automatización inteligente para los desafíos de reembolso en el cuidado de la salud.
La iniciativa aborda una necesidad crítica, ya que los costos administrativos representan más del 40% de los gastos hospitalarios en EE. UU., con más de 160 mil millones de dólares gastados anualmente en la gestión del ciclo de ingresos. El amplio alcance de R1, que atiende a 94 de los 100 principales sistemas de salud de EE. UU., proporciona acceso a un extenso conjunto de datos, incluyendo:
- más de 180 millones de transacciones anuales de pagadores
- 550 millones de encuentros anuales con pacientes
- 20,000 algoritmos de pago propietarios
- 1.2 mil millones de acciones de flujo de trabajo anuales
El laboratorio, ya operativo, está desarrollando aplicaciones impulsadas por inteligencia artificial para tareas como codificación, facturación y gestión de denegaciones. R1 planea implementar soluciones completas de 'trabajadores RCM agentivos' para clientes empresariales en la segunda mitad de 2025.
R1과 Palantir Technologies (NASDAQ:PLTR)는 R37라는 고급 인공지능 연구소를 출범하기 위해 협력했습니다. 이 연구소는 의료 재무 성과를 혁신하는 데 중점을 두고 있습니다. 이 협력은 R1의 방대한 수익 주기 관리 전문성과 Palantir의 인공지능 능력을 결합하여 의료 환급 문제를 위한 지능형 자동화 솔루션을 개발합니다.
이 이니셔티브는 행정 비용이 미국 병원 비용의 40% 이상을 차지하고 있으며, 매년 1,600억 달러 이상이 수익 주기 관리에 사용되는 중요한 필요를 해결합니다. R1은 미국의 100대 건강 시스템 중 94곳에 서비스를 제공하여 다음과 같은 방대한 데이터에 접근할 수 있습니다:
- 연간 1억 8천만 건 이상의 지급자 거래
- 연간 5억 5천만 건의 환자 만남
- 20,000개의 독점 지급 알고리즘
- 연간 12억 건의 워크플로우 작업
이미 운영 중인 이 연구소는 코딩, 청구 및 거부 관리와 같은 작업을 위한 AI 기반 애플리케이션을 개발하고 있습니다. R1은 2025년 하반기에 기업 고객을 위한 포괄적인 '대리 RCM 작업자' 솔루션을 배포할 계획입니다.
R1 et Palantir Technologies (NASDAQ:PLTR) ont établi un partenariat pour lancer R37, un laboratoire avancé d'intelligence artificielle axé sur la transformation des performances financières dans le secteur de la santé. Cette collaboration combine l'expertise étendue de R1 en gestion du cycle de revenus avec les capacités d'intelligence artificielle de Palantir pour développer des solutions d'automatisation intelligente pour les défis de remboursement dans le domaine de la santé.
Cette initiative répond à un besoin critique, car les coûts administratifs représentent plus de 40 % des dépenses hospitalières aux États-Unis, avec plus de 160 milliards de dollars dépensés chaque année pour la gestion du cycle de revenus. L'ample portée de R1, qui dessert 94 des 100 principaux systèmes de santé américains, permet d'accéder à un vaste ensemble de données, y compris :
- plus de 180 millions de transactions annuelles de payeurs
- 550 millions de rencontres annuelles avec des patients
- 20 000 algorithmes de paiement propriétaires
- 1,2 milliard d'actions de flux de travail annuelles
Le laboratoire, déjà opérationnel, développe des applications alimentées par l'intelligence artificielle pour des tâches telles que le codage, la facturation et la gestion des refus. R1 prévoit de déployer des solutions complètes pour des 'travailleurs RCM agentiques' auprès de clients entreprises dans la seconde moitié de 2025.
R1 und Palantir Technologies (NASDAQ:PLTR) haben sich zusammengeschlossen, um R37 zu starten, ein fortschrittliches KI-Labor, das sich auf die Transformation der finanziellen Leistung im Gesundheitswesen konzentriert. Die Zusammenarbeit kombiniert R1s umfangreiche Expertise im Revenue Cycle Management mit Palantirs KI-Fähigkeiten, um intelligente Automatisierungslösungen für Herausforderungen im Gesundheitswesen zu entwickeln.
Die Initiative spricht ein kritisches Bedürfnis an, da die Verwaltungskosten über 40 % der Krankenhausausgaben in den USA ausmachen, wobei jährlich mehr als 160 Milliarden Dollar für das Revenue Cycle Management ausgegeben werden. R1s erheblicher Einfluss, der 94 der 100 größten Gesundheitssysteme in den USA bedient, bietet Zugang zu umfangreichen Daten, darunter:
- über 180 Millionen jährliche Zahlungen
- 550 Millionen jährliche Patientenkontakte
- 20.000 proprietäre Zahlungsalgorithmen
- 1,2 Milliarden jährliche Workflow-Aktionen
Das Labor, das bereits in Betrieb ist, entwickelt KI-gestützte Anwendungen für Aufgaben wie Codierung, Abrechnung und Management von Ablehnungen. R1 plant, in der zweiten Hälfte des Jahres 2025 umfassende 'agentische RCM-Arbeiter'-Lösungen für Unternehmenskunden bereitzustellen.
- Strategic partnership with major healthcare RCM provider R1 expands PLTR's presence in healthcare sector
- Access to massive healthcare data repository for AI development
- AI solutions already showing transformational benefits in initial testing
- Addresses $160B+ market opportunity in healthcare RCM
- Integration with 94 of top 100 U.S. health systems provides immediate scale
- Commercial deployment not expected until second half of 2025
- Success depends on effective integration of complex healthcare systems
Insights
Palantir's partnership with R1 to launch R37 represents a strategic expansion into healthcare financial operations - a massive market with
The partnership provides Palantir with two immediate strategic advantages: access to R1's extensive client base (94 of the top 100 U.S. health systems) and leverage of R1's massive data repository (180+ million annual payer transactions, 550 million patient encounters). This data-rich environment creates an ideal application scenario for Palantir's AI systems.
What differentiates this deal is Palantir's direct operational integration, with engineers embedded within R1's operations - signaling a deeper partnership than typical technology licensing arrangements. The lab is already operational and showing positive results in testing, though full commercial deployment to enterprise customers won't begin until H2 2025.
While immediate revenue impact will be minimal, this partnership demonstrates Palantir's continued expansion of its commercial AI applications beyond government contracts into specialized enterprise workflows, specifically addressing operational inefficiencies in healthcare administration. The focus on "agentic" AI solutions also aligns with Palantir's strategic emphasis on autonomous AI agents for complex operational tasks.
Administrative costs now account for more than
R1’s extensive reach—serving 94 of the top 100 U.S. health systems—uniquely positions it to transform RCM. R1 has been supporting automated revenue cycle workflows at scale across the largest repository of proprietary RCM structured and unstructured data. The repository includes: 180 million+ annual payer transactions, 550 million annual patient encounters, 20,000 proprietary payment algorithms, and 1.2 billion annual workflow actions. By integrating Palantir’s AI tools and capabilities with R1’s existing technology and domain expertise, R37 can unlock faster, more precise scalable reimbursement outcomes.
“R1 is thrilled to partner with Palantir to bring the transformational power of agentic AI to the revenue cycle through R37,” said Joe Flanagan, CEO of R1. “With our leading experts in reimbursement and history of automation, this lab will further accelerate investments on behalf of providers and create a new revenue cycle that delivers a faster, frictionless, and more transparent financial experience for both providers and patients.”
"R1 brings unmatched ambition to an area of healthcare that desperately needs it,” said Alex Karp, co-founder and CEO of Palantir Technologies. “By embedding our engineers directly within R1’s operations, we can rapidly scale intelligent automation and drive measurable impact at speed—ultimately enabling providers to focus on delivering better patient care.”
The lab has been operational for months and has been producing AI-powered agentic applications that are already driving transformational benefits in initial batch testing. R1 expects to deploy comprehensive ‘agentic RCM worker’ solutions to a group of enterprise customers in the second half of 2025.
About R1
R1 is a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while driving revenue yield, reducing operating costs, and enhancing the patient experience. To learn more, visit: https://www.r1rcm.com.
About Palantir Technologies Inc.
Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of a contract and the expected benefits of Palantir’s software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond Palantir’s control. These risks and uncertainties include the ability to meet the unique needs of customers; the failure of Palantir’s platforms to satisfy customers or perform as desired; the frequency or severity of any software and implementation errors; Palantir’s platforms’ reliability; and customers’ ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings Palantir makes with the Securities and Exchange Commission from time to time. Except as required by law, Palantir does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250314502212/en/
R1 Contact
Yancey Casey
Amendola Communications
ycasey@acmarketingpr.com
Will Reilly
VP, Growth Marketing
reilly@r1rcm.com
Palantir Contact
Lisa Gordon
media@palantir.com
Source: Palantir Technologies Inc.
FAQ
What is the purpose of R1 and Palantir's R37 AI lab partnership?
When will R1 deploy the R37 AI solutions to enterprise customers?
How many healthcare systems does R1 currently serve?
What percentage of U.S. hospital expenses are currently spent on administrative costs?
